The updated data from the iMMagine-1 Phase 2 trial for anito-cel in relapsed/refractory multiple myeloma presented at ASH 2024 showed promising results. Anito-cel demonstrated an improved overall ...
Additionally, the safety profile of anito-cel was favorable, with no severe neurotoxicity events and manageable rates of cytokine release syndrome and neurotoxicity. The trial showed that anito ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback